Dr Jo Perry
One of the most successful strategies for treating breast cancer has been the use of humanised monoclonal antibodies to target secreted growth factors or cell surface receptors whose function has been upregulated in the tumour.
Development of inhibitors of PC-PLC as anticancer therapeutics
Associate Professor David Barker
Many patients with metastatic breast cancer do not respond to conventional chemotherapy and better strategies to treat these patients are urgently needed.
Using CRISPR-Cas9 to predict sensitivity to trastuzumab emtansine
Dr Francis Hunter
Over 3000 diagnoses and 600 deaths are attributable to breast cancer in New Zealand each year.
Targeting HP1 regulated pathways to suppress breast cell invasion
Dr Tracy Hale
Metastasis is the primary cause of death in breast cancer patients as it refractory to current therapies.
Testing a new drug target that promises to impair breast cancer cell growth
Although breast cancer cells have heterogeneous properties, all of them have a high nutritional demand.
Read moreIdentifying breast cancer patients with clinically relevant mutations
Associate Professor Logan Walker
Identification of cancer-causing mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, has well-defined and actionable implications for disease prevention.
Developing a molecular “fingerprint” as a non-invasive screen for breast cancer
Dr Annette Lasham
This translational grant proposes to build on exciting BCRT-funded science that has led to the identification of two RNA markers in the blood, which together may be able to indicate whether a woman has breast cancer or not.
Synthetic lethal targeting of lobular breast cancer
Professor Parry Guilford
The inactivation of tumour suppressor genes is the most common of all genetic events in cancer but not one that can be targeted by conventional therapy, because the tumour suppressor protein is lost from the cancer cell.
Inhibiting the human GH receptor with small molecule antagonists
Dr Jo Perry
Localised production of growth hormone (GH) is detectable in a variety of different human cancers, including breast cancer, and this is associated with an increased risk of metastasis and reduced survival for breast cancer patients.
SHON as a novel biomarker predicting endocrine therapy response in breast cancer
Dr Dong Xu-Lui
Breast cancer affects 1 in 9 New Zealand women. Anti-estrogens such as tamoxifen have been used to treat estrogen receptor positive (ER+) breast cancer and reduce the annual death rate by approximately one third.